Ryan David Lake - 05 Jun 2021 Form 4 Insider Report for Recro Pharma, Inc.

Role: Chief Financial Officer
Signature: /s/ Ryan D. Lake
Issuer symbol: N/A
Transactions as of: 05 Jun 2021
Net transactions value: -$1,654
Form type: 4
Filing time: 08 Jun 2021, 17:04:06 UTC
Next filing: 13 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SCTL	Common Stock	Options Exercise		+2,500	+0.66%		379,064	05 Jun 2021	Direct	F1
transaction	SCTL	Common Stock	Tax liability	$1,654	-719	-0.19%	$2.30	378,345	07 Jun 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCTL	Restricted Stock Units	Options Exercise	$0	-2,500	-100%	$0.000000^*	0	05 Jun 2021	Common Stock	2,500		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3	On June 5, 2017, the reporting person was granted 10,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.